Privacy preserving validation for multiomic prediction models | JoVE Visualize

Area of Science:

Bioinformatics
Computational Biology
Cancer Research

Background:

Reproducibility of ribonucleic acid (RNA) data analysis across different laboratories is a significant challenge in cancer research.
Variations in RNA library preparation and quantification hinder the application and validation of molecular predictors on new datasets.
Current RNA correction methods often require access to sensitive patient-level data, limiting data sharing and predictor validation.

Purpose of the Study:

To introduce SpinAdapt, an unsupervised RNA correction algorithm designed to facilitate the transfer of molecular models without necessitating patient-level data access.
To address the critical need for enhanced research reproducibility and patient data privacy in multi-dataset RNA analyses.
To develop a method that enables unbiased evaluation of predictors on validation cohorts.

Main Methods:

SpinAdapt employs an unsupervised approach to compute data corrections using only aggregate statistics from each dataset.
This method ensures patient data privacy by avoiding direct access to individual-level information.
The algorithm's performance is evaluated against established methods like Seurat and ComBat using publicly available cancer datasets.

Main Results:

SpinAdapt demonstrates superior performance compared to existing RNA correction methods, including Seurat and ComBat, on TCGA and ICGC cancer studies.
The algorithm successfully corrects new samples, allowing for unbiased evaluation on independent validation cohorts.
Despite the inherent privacy-performance trade-off, SpinAdapt achieves robust results while preserving patient data confidentiality.

Conclusions:

SpinAdapt offers a novel paradigm for RNA data correction, significantly enhancing research reproducibility in cancer studies.
The algorithm effectively enables the transfer of molecular models across datasets while upholding stringent patient data privacy standards.
This approach is expected to accelerate the validation and clinical translation of molecular predictors in cancer research.